Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Marc S. Hoffmann, Javier L. Munoz, Jason Westin, Theodoros Vassilakopoulos, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Wojciech Jurczak, Su-Peng Yeh, Maria Bouzani, Argyrios Gkasiamis, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2023-174242

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Jason Westin, Alejandro Martín García-Sancho, Marc Hoffmann, Theodoros P. Vassilakopoulos, Su-Peng Yeh, Argyrios Gkasiamis, Poliana Patah, Arpankumar Patel, Ju Li, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 9475–9477.

https://doi.org/10.1182/blood-2022-162774

Published: 2022

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 m ND-AML Treated with Ivo+AZA in the AGILE Study

Blood (2022) 140 (Supplement 1): 539–542.

https://doi.org/10.1182/blood-2022-159473

Published: 2022

Journal Articles

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Keith W. Pratz, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Jun-Ho Jang, Su-Peng Yeh, Grace Ku, Ying Zhou, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 529–531.

https://doi.org/10.1182/blood-2022-158518

Published: 2022

Journal Articles

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood (2022) 140 (3): 285–289.

https://doi.org/10.1182/blood.2022015832

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Blood (2021) 138 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2021-148431

Published: 2021

Journal Articles

AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos, Christian Recher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su-Peng Yeh, Scott R. Daigle, Jianan Hui, Vickie Zhang, Shuchi S. Pandya, Diego A. Gianolio, Stephane de Botton, Hartmut Döhner

Blood (2021) 138 (Supplement 1): 697.

https://doi.org/10.1182/blood-2021-147805

Published: 2021

Journal Articles

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Kihyun Kim, Natalia Paola Schutz, Su-Peng Yeh, Estelle Verburgh, Fahad Alsharif, Wenming Chen, Tatiana Mitina, Wee-Joo Chng, Cathy Wu, Hui Wan, Zhongwen Huang, Meral Beksac

Blood (2021) 138 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2021-147108

Published: 2021

Journal Articles

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Burhan Ferhanoglu, Marta Zerga, Mubarak Al-mansour, Tae Min Kim, Su-Peng Yeh, Yuqin Song, Amado J Karduss, Gayane Tumyan, Soon Thye Lim, Silvia Rivas-Vera, Yok Lam Kwong, Kwang-Wei Wu, Zhongwen Huang, Mark Hertzberg

Blood (2021) 138 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2021-145838

Published: 2021

Journal Articles

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Burhan Ferhanoglu, MD, Tae Min Kim, MD PhD, Amado Karduss, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, MD, Yuqin Song, MD PhD, Silvia Rivas-Vera, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, Su-Peng Yeh, MD, Arif Abdillah, MD, Zhongwen Huang, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg, MBBS PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-134885

Published: 2020

Journal Articles

A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms

Hirohiko Shibayama, MD PhD, Hirokazu Tanaka, MD PhD, Su-Peng Yeh, MD, Hui-Hua Hsiao, MD, Silpa Nuthalapati, PhD, Kota Ono, PhD, Kotaro Uehara, MS, Sumiko Okubo, MD PhD, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137068

Published: 2020

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-133912

Published: 2020

Journal Articles

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Hsin-An Hou, Chien-Chin Lin, MD, Ming-Chung Kuo, MD, Shyuann-Yuh Lin, MD, Jyh-Pyng Gau, MD, Ming-Chung Wang, MD, Ming-Chih Chang, MD, Tsung-Chih Chen, MD, Su-Peng Yeh, MD, Yeu-Chin Chen, MD, Cih-En Huang, MD, Chieh-Wen Chen, MD, Yee-Ming Lee, PhD, Fan-Chen Ku, MD, Lee-Yung Shih, MD

Blood (2019) 134 (Supplement_1): 5374.

https://doi.org/10.1182/blood-2019-129645

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Blood (2019) 134 (Supplement_1): 2591.

https://doi.org/10.1182/blood-2019-127253

Published: 2019

Journal Articles

Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Su-Peng Yeh, MD, Fahad Alsharif, MD DIM, MB ChB, Meral Beksac, MD, Wenming Chen, PhD, Dorotea Fantl, MD, Tatiana Mitina, MD PhD, Estelle Verburgh, MBChB, M MDInt, FCPSA, PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Kwang-Wei Wu, MD, Zijing Zhang, PhD, Hui Wan, MD PhD, Kihyun Kim, MD

Blood (2019) 134 (Supplement_1): 5577.

https://doi.org/10.1182/blood-2019-122732

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

NARROW

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 m ND-AML Treated with Ivo+AZA in the AGILE Study

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Use of Positron Emission Tomography in Patients with Classical Hodgkin Lymphoma Outside of Europe and North America: Results from the International, Multi-Center, Retrospective B-Holistic Study

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only